Targeted Anticancer Therapies (TAT) Congress Becomes an Annual ESMO Event
ESMO has announced it will take over the organisation of the Targeted Anticancer Therapies (TAT) Congress series, with the aim of expanding its educational offer and ensure that professionals are kept up to date with the latest drug developments to improve outcomes for cancer patients